The market for Parkinson's Disease treatments, including L-dopa-based standard therapies, is already worth $5.2 billion, but the development of new therapies is urgently needed due to the occurrence of various side effects and worsening of symptoms induced by the drugs.

ID119040388 is a single treatment drug targeting patients with early Parkinson's disease. Not only does a single dose of the drug improve movement disorders caused by Parkinson's disease, but long-term treatment has also been shown to progressively improve cognitive function. We are planning a Phase I clinical trial in 2025 and are in discussions with major global pharmaceutical companies for technology export and joint development.